Current Treatment Landscape in First-

line Urothelial Cancer

6th Annual International Breast Cancer Conference & Precision Oncology 2022 JAIPUR

Dr Ashish Joshi MD DM Consultant Medical Oncologist Director and Co Founder Mumbai Oncocare Centre (MOC)



A.5% of patients have metastatic disease at the time of diagnosis.

B.50 %patients relapse after cystectomy depending on the pathologic stage of the tumor and nodal status 1)10% to 30% Local recurrences 2)70 %-distant metastases.

	т	N	M
Stage IIIB	T1-T4a	N2,N3	MO
Stage IVA	T4b	Any N	MO
	Any T	Any N	M1a
Stage IVB	Any T	Any N	M1b



- M Distant Metastasis
- M0 No distant metastasis
- M1 Distant metastasis
 - M1a Distant metastasis limited to lymph nodes beyond the common iliacs

M1b Non-lymph-node distant metastases

Some basic facts...

 1. Metastatectomy for oligometastatic disease -carefully select appropriate patients for metastasectomy,

- 2. If the evidence of spread is limited to nodes and biopsy is technically feasible, nodal biopsy should be considered and patients should be managed for positive nodal disease (stage IIIA, stage IIIB, or stage IVA).
- 3. Advanced urothelial cancers -93% of cases had at least one clinically relevant genetic alteration, with a mean of 2.6 clinically relevant genetic alterations per case.

Broad scheme of discussion

- 1.Chemotherapy 1 st line
- 2.ICI post chemotherapy- Maintenance
- 3.ICI 1 st line when and how ?



1.Chemotherapy – 1 st line

- 1. GC = standard MVAC @efficacy
- 2.GC >>>MVAC @ toxicity
- 3. ddMVAC >>> standard MVAC



• 5.Addition of third drug – Taxanes – questionable benefits .



2.ICI Post chemotherapy- Avelumab Maintenance Therapy


- phase III JAVELIN Bladder 100 trial
- N= 700
- OS- 21.4 vs. 14.3 months; HR, 0.69; 95% CI, 0.56–0.86; P = .001).
- Toxicity comparable
- PDL 1 agnostic
- Post Cisplatin based chemotherapy category 1 recommendations



3.ICI – 1 st line when and how ?

- A. Platinum eligibility patient selection
- B.ICI evidence and action Atezolizumab / Pembrolizumab





1. Bellmunt et al. Ann Oncol 2014 (eUpdate 2020)
2. NCCN Guidelines – Bladder cancer v6.2020

Some basic facts ...

1.decreased survival –ICI -first-line monotherapy compared to those receiving cisplatin- or carboplatin-based therapy

2. Choose chemotherapy even for PDL 1 high platinum eligible patient .

3. Do we need PD L1 checking at all? – Yes - for Atezolizumab

4. Chemotherapy + ICI << ICI monotherapy.

a. Atezolizumab- IMVIGOR 210/130b. Pembrolizumab- Keynote 052/361



IMvigor210 Cohort 1: phase II single-arm study of atezolizumab in mUC

Key Cohort 1-specific inclusion criteria

- Locally advanced/metastatic transitional cell carcinoma of the urothelium
- FFPE tissue specimen for PD-L1 analysis
- No prior treatment for mUC (>12 months since perioperative chemotherapy)
- ECOG PS 0–2
- Cisplatin ineligibility based on ≥1 of: impaired renal function (GFR >30 and <60mL/min); Grade ≥2 hearing loss; Grade ≥2 peripheral neuropathy; ECOG PS 2

N=119

Primary endpoint

ORR (IRF assessed by RECIST v1.1)

Data from IMvigor210 Cohort 1 supported the FDA accelerated and EMA approvals of atezolizumab for 1L, cisplatin-ineligible mUC^{2,3}

Atezolizumab


Secondary endpoints

 PFS and DOR (IRF assessed by RECIST v1.1 and investigator assessed by modified RECIST*); ORR, DOR and PFS (investigator assessed by RECIST v1.1); OS and safety, tolerability, PKs and ATAs

PD

Patients with CR/PR/SD followed every 12 weeks (follow-up until death, loss to follow-up or study termination). Response 1767; 2. Atezolizumab PI assessed by CT scan (RECIST v1.1 and modified RECIST. * Modified RECIST criteria account for possible appearance brance b lesions and allow radiological progression to be confirmed at a subsequent assessment

IMvigor210 Cohort 1: ORR and OS in the ITT population




- *19 patients with missing or unevaluable response status. ⁺No death or IRF-assessed PD events (RECIST v1.1). Data cut-off: 12 July 2017; median duration of follow-up: 29.3 months
- 1. Balar et al. ASCO 2018; 2. Loriot et al. ASCO 2019

IMvigor210 Cohort 1: DOR in responders


DOR in patients with CR (n=10)

	N=119	_
Median duration of follow-up, months	29.3	
Median duration of follow-up for patients with CR, months	31.7	
ORR (95% CI), %* CR, %	24 (16–32) 8	
Median duration of response in patients with CR (95% CI), months	Not reached (NE–NE)	
Median duration of complete response (95% CI), months	Not reached (NE–NE)	
Ongoing CR at data cut-off, n (%) [¶]	8 (80)	



*19 patients with missing or unevaluable response status
*Discontinued due to an AE. *Discontinued due to other reasons. \$Discontinued due to patient withdrawal
*Befers to no PD or death only. Data cut-off: 12 July 2017: median follow-up: 29.3 months


• Loriot et al. ASCO 2019



 Error bars refer to 95% CI for median OS; *upper CI is NE; [‡]median is NE. Data cut-off: 12 July 2017; median follow-up: 29.3 months

• Balar et al. ASCO GU 2019

IMvigor130: phase III study of atezolizumab ± platinum-based chemotherapy for 1L mUC




Primary endpoints

 Investigator-assessed PFS* and OS (Arm A vs C); OS (Arm B vs C; hierarchical approach)

Secondary endpoints

- INV-ORR*, DOR
- PFS, and OS (Arm B vs C; PD-L1 subgroups)
- Safety


IMvigor130: PFS (ITT, Arm A vs Arm C, co-primary endpoint)



• Data cut-off 31 May 2019; median survival follow-up 11.8 months (all patients)

• Grande et al. ESMO 2019; Galsky et al. Lancet 2020

IMvigor130: interim OS analysis (ITT, Arm A vs Arm C)



Data cut-off 31 May 2019; median survival follow-up 11.8 months (all patients)
*5% of patients from Arm A and 20% of patients from Arm C crossed over to non-protocol immunotherapy
*Did not cross the interim efficacy boundary of 0.007 per the O'Brien-Fleming alpha spending function


Grande et al. ESMO 2019; Galsky et al. Lancet 2020

IMvigor130: interim OS by PD-L1 status

vs Arm C (placebo + platinum/gemcitabine) 100 Arm A IC0/1 (n=243) Arm A IC2/3 (n=99) Arm C IC0/1 (n=231) 80 Arm C IC2/3 (n=81) Log-rank p=0.079 60 -OS (%) 40 -20 months 15.9 13.1 months months 23.6 months 0 -32 20 24 28 0 8 12 16 Time (months)

Arm A (atezolizumab + platinum/gemcitabine)

Arm B (atezolizumab) vs Arm C (placebo + platinum/gemcitabine)



• P values are displayed for exploratory/descriptive purposes only

• Baseline PD-L1 expression in tumour specimens was evaluated using the

Atezolizumab – 1 st line

1) are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 as measured by PD-L1–TPS 5 % (SP 142)

2) are not eligible for any platinum- containing chemotherapy regardless of the level of tumor PD-L1 expression.

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

Arjun V Balar, Daniel Castellano, Peter H O'Donnell, Petros Grivas, Jacqueline Vuky, Thomas Powles, Elizabeth R Plimack, Noah M Hahn, Ronald de Wit, Lei Pang, Mary J Savage, Rodolfo F Perini, Stephen M Keefe, Dean Bajorin, Joaquim Bellmunt First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study






Figure 2: Centrally assessed tumour response to pembrolizumab according to Response Evaluation Criteria in Solid Tumors (version 1.1)

(A) Treatment exposure and duration of response in patients achieving a partial response or complete response (n=89). (B) Best percentage change from baseline in target lesions (n=331). Patients who had measurable disease at baseline and at least one post-baseline scan are included.



First Line combination trials



Monotherapy Atezo/Pembro arms were <u>halted</u> by the FDA after PD-L1 low group had decreased survival

** Atezo/Pembro could be continued until disease progression

Pembrolizumab – 1 st line

Only patients who were not eligible for any platinum-containing chemotherapy




First Line immune checkpoint inhibitors

	Pembrolizumab	Atezolizumab		
Phase	Phase II (Keynote-052)	Phase II (IMvigor 210, Cohort 1)		
Patients	370	119		
Dosing	200 mg every 3 weeks	1200 mg every 3 weeks		
ORR	28.9% (9.5% CR)	23% (9% CR)		
Duration of response	39.4% responses ongoing at ≥48 months	70% responses ongoing at 17.2 months		
Median 0S	11.3 months	15.9 months		
Median PFS	2months	2.7 months		
Rate of grade 3/4 treatment-related AEs (%)	19	16		
AE, adverse events; CR, complete response; ORR, objective response rate; OS, overall survival; PFS, progression free survival				



Management algorithm



Recruiting trials in 1L setting for advanced urothelial carcinoma

Study name/ID	Investigational drug	Phase	Primary end point
EV-301 (Clinicaltrial.gov identifier: NCT04223856)	Enfortumab-vedotin	Ш	OS, PFS
LEAP-011 (NCT03898180)	Sacituzumab-govitecan	ш	OS, PFS
NCT03967977	Tislelizumab	ш	OS
NCT04486781	sEphB4-HAS + pembrolizumab	П	ORR
NCT04601857	Futibatinib + pembrolizumab	н	ORR
AUREA (NCT04602078)	Atezolizumab + split dose cisplatin/gemcitabine	Ш	ORR
NCT04264936	RC48-ADC and JS001	Ib/II	Adverse events and maximal tolerated dose
NCT03534804	Cabozantinib + pembrolizumab	н	ORR
FORT-2 (NCT03473756)	Rogaratinib + atezolizumab	н	Dose-limiting toxicity, TRAE, PFS
NCT03237780	Eribulin mesylate + atezolizumab	П	ORR, TRAE, OTR
GCISAVE (NCT03324282)	Avelumab + chemotherapy	П	ORR, proportion of severe toxicity
NCT03272217	Atezolizumab + Bevacizumab	П	0S

OS, overall survival; ORR, objective tumor response; PFS, progression free survival; TRAE, treatment related adverse events.

PD-L1/PD-1 inhibitors have been approved for 1L mUC



1L PD-L1+ cisplatin-ineligible

1L platinum-ineligible 1L maintenance



Gemcitabine/cisplatin

Pembrolizumab Atezolizumab emcitabine/carboplatin



Gemcitabine/cisplatin

Pembrolizumab Atezolizumab mcitabine/carboplati Pembrolizumab Atezolizumab Regardless of tumor PD-L1 expression

Avelumab

